Do the numbers hold clues to what lies ahead for the stock Zacks Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release. RAPT Therapeutics started at overweight with 61 stock price target at J.P. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00 and -33.38, respectively, for the quarter ended September 2021.
and changed its name to RAPT Therapeutics, Inc. Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating Performance Dividends Ownership. The company was formerly known as FLX Bio, Inc. (NASDAQ:RAPT) shares gapped down prior to trading on Thursday after the company announced weaker than expected quarterly earnings. RAPT Therapeutics Inc Ordinary Shares RAPT. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. 10, 2021 (GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. RAPT Therapeutics Announces Proposed Public Offering of 125M Of Common Stock.
Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. RAPT Therapeutics Raises 125M Via Equity At 6 Discount. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.